Effects of olanzapine and aripiprazole on lipolysis in healthy human subcutaneous adipocytes during short incubations.

Assel Sarsenbayeva1*, Cátia Marques1, Gretha Boersma1, Maria João Pereira1, Jan Eriksson1

1Department of Medical Sciences, Uppsala University, Uppsala, Sweden

*Corresponding author:
Assel Sarsenbayeva, Uppsala University, Uppsala, Sweden. E-mail: assel.sarsenbayeva@medsci.uu.se

Keywords: Adipocytes, olanzapine, aripiprazole.

Published April 10, 2018.

Copyright: © 2018 Author. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Editor: Alberto M. Borobia Pérez.


Funding: This work is being supported by Marie Skłodowska Curie Actions (H2020-MSCA-ITN-2016).

Competing Interests: The authors declare no conflicts of interest.

Introduction: Second-generation Antipsychotics (SGAs) have become the treatment of choice over the typical antipsychotics as they provide excellent efficacy and fewer extrapyramidal symptoms. However, the compliance of the patients to SGAs is negatively affected by their ability to induce or aggravate metabolic syndrome, namely, weight gain, insulin resistance, and Type 2 Diabetes. The exact underlying mechanism of metabolic effects of SGAs is not fully elucidated and it is assumed to be at least partially due to their effect on central nervous system. However, whether SGAs have a direct effect on insulin action in the tissues is still to be elucidated. The effect of SGAs on body metabolism varies and we have chosen two drugs, Olanzapine and Aripiprazole, which are associated with high and low risk of metabolic side-effects, respectively.

Our research is focused on studying the effect of both SGAs on insulin resistance in human adipose tissue. Aside from lipid storage function, adipose tissue has been recognised, as an endocrine organ, producing hormones, such as adiponectin and leptin, indispensable for energy homeostasis. The set of experiments performed as a part of this study includes measuring the effect of Olanzapine and Aripiprazole on the lipolysis in human isolated adipocytes.

Methods: Biopsies of subcutaneous adipose tissue (SAT) were collected from 6 patients (3 men, 3 women; age: 20-76 years; BMI: 20.9-34.5 kg/m2). Subjects were free of antidepressants or antipsychotics treatment. At the moment, only the effect of Olanzapine has been tested and measured, the experiments with Aripiprazole are in progress.

A 6% adipocyte suspension was incubated with olanzapine (0.004, 0.04, 0.1, 0.2, 2 and 20 µM) or aripiprazole (0.02, 0.2, 0.5, 1, 10 and 100 µM). This was followed by 10 minutes incubation with 4 concentrations of insulin (0.1 µU; 1.0 µU; 10 µU; 100 µU) and then incubated with 0.5 µM β-adrenergic receptor agonist, Isopretenerol, for 1h 50 min. β-adrenergic stimulation activates hormone-sensitive lipase (HSL) enzyme via cAMP-dependent pathway. HSL, in turn, hydrolyses triacylglycerol (TAG), diacylglycerol (DAG) or monoacylglycerol (MAG) molecules producing free fatty acids and glycerol. The supernatant was then collected and used for glycerol measurement.

Results: Short incubations of adipocytes with therapeutic concentrations of Olanzapine show no effect in lipolysis. The highest concentration of the drug hints at a reduced rate of lipolysis in adipocytes by more than 50% for each insulin concentration (p<0.0001) and in control conditions (p<0.01).

Conclusions: Therefore, it seems that short-term incubation of adipocytes with 20 µM Olanzapine reduces the rate of lipolysis, while the therapeutic concentrations do not seem to alter lipolysis in adipocytes.